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Abstract Monoclonal antibodies used to distinguish between 
dystrophin and utrophin were systematically applied to skeletal 
muscles containing arteries and veins. Small arteries were found 
to contain long forms of both utrophin and dystrophin, while 
small veins contained only long forms of utrophin. In addition, all 
sizes of vascular smooth muscles were demonstrated to contain 
another related Mr 80 kDa protein (possibly a short utrophin 
transcript). Regardless of their tissue distributions, we assumed 
that each of these molecules had distinct properties, i.e. 
dystrophin with a mechanical function and utrophin with an 
architectural function. This difference in the roles of dystrophin 
and utrophin could reduce the efficiency of protection against 
muscle membrane degeneration when utrophin overexpression is 
programmed. 
© 1997 Federation of European Biochemical Societies. 
1. Introduction 
Molecular events leading to Duchenne muscular dystrophy 
(DMD) result from a deficiency in dystrophin, a protein en-
coded at the Xp21 locus. The function of this molecule in the 
cytoskeletal-membrane system is not yet fully characterized, 
whereas its primary structure has long been established [1]. 
Dystrophin has extensive homology with other rod-like struc-
tures present in alpha-actinin and spectrin [2]. The N-terminal 
portion of this molecule shares homology sequences with both 
of the above proteins and an actin binding domain is known 
to be present [3]. The C-terminal end is specific to dystrophin 
and is part of a complex with glycoproteins [4-10]. 
Different proteins show homology with dystrophin, partic-
ularly with sequential C-terminal parts [11-16]. The existence 
of long and short molecules in this dystrophin family, such as 
utrophin (DRP1) and DRP2 [15,16], suggests that each mem-
ber of the 'dystrophin group of proteins' may have a specific 
function in different tissues [17,18]. It would thus be impor-
tant to determine the specific functional differences between 
dystrophin and utrophin. This prompted us to investigate 
vessel tissues which naturally contain dystrophin and utrophin 
[19]. This study was carefully conducted on the basis of 
known differences between arteries and veins. Arteries mainly 
have a mechanical role, i.e. they are structurally able to resist 
blood flow propulsed by cardiac systole, and this force is 
propagated as an elastic response. In contrast, veins are 
more extensive (2-fold more veins than arteries), and their 
paths generally vary more than those of arteries. Vein diam-
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eters can increase 5-fold, while arteries can only dilate 2-fold. 
However, the major difference is that arteries are responsible 
for active work, while veins have a passive function with re-
spect to blood transit. 
This study focused on possible differences in the presence of 
dystrophin versus utrophin in both kinds of vessels (arteries 
and veins). This included: (i) conducting a detailed analysis to 
compare dystrophin/utrophin distributions in these different 
smooth muscles relative to those in skeletal muscles, and (ii) 
characterizing the protein size (long or short forms) in each 
vessel. We identified the protein using region-specific mono-
clonal antibodies directed against each member of the dystro-
phin family. Two complementary approaches were used: im-
munofluorescence detection on cryostat sections and Western 
blot analyses of various crude protein extracts from different 
tissues. Our results provided indirect evidence of functional 
differences between dystrophin and utrophin. 
2. Materials and methods 
Rabbit skeletal muscles at the adult development stage (12 months 
after birth) were examined. Various leg striated muscles were analyzed 
for their vessel contents (arteries and veins). Arteries and veins were 
differentiated on the basis of size. Both structures were easily isolated 
due to the clear shape of large arteries (round) and large veins (more 
elongated). 
2.1. Immunofluorescence detection 
Serial 10 μιη transverse cryostat sections of rabbit skeletal muscle 
containing vessels were labelling with different specific antibodies. The 
following panel of antibodies was used: monoclonal dystrophin-spe-
cific antibodies 5G5 and 12G9 (both produced in our laboratory [20-
22]), and Dys 2 (Novocastra); monoclonal utrophin-specific antibod-
ies, 5B1 (produced in our laboratory), and 12B6 (NCL-DRP1, Novo-
castra) ; a specific monoclonal antibody (5F3) directed against the last 
31 amino acids of Dp 71 [23]; a universal antibody (5A3) detecting 
both dystrophin and utrophin (produced in our laboratory [20-22]). 
Specific labelling of each antibody on sections was detected with fluo-
resceine-conjugated goat anti-mouse IgG (1/100, from Sigma Immu-
nochemical). 
2.2. Immunoblot analysis 
Tissues were homogenized in buffer containing 5% SDS, 5% β-
mercaptoethanol, 1 mM PMSF, 0.1 mg/ml soybean trypsin inhibitor, 
0.1 mg/ml leupeptine, 1 mM iodoacetamide, 15% glycerol, 0.001% 
bromophenol and 50 mM Tris-HCl (pH 9.0). Fifty milliliters of 
each sample was denatured by boiling for 2 min and loaded on 0.75 
mm SDS-polyacrylamide 8% gels with stacking gel. After SDS-PAGE 
migration, the proteins were electrotransferred onto nitrocellulose 
sheets overnight (30 V, 100 mA) in the presence of 0.1% SDS in the 
transfer buffer (25 mM Tris-HCl, 192 mM glycine, 0.1% SDS and 
20% methanol). Nitrocellulose membranes (0.2 μpiι) were blocked 
with 3% BSA dissolved in TBST buffer (fO mM Tris-HCl, 150 mM 
NaCl, 0.05% Tween-20, pH 8) for 30 min at room temperature. Blots 
were incubated at room temperature for 1 h with specific monoclonal 
(5B1, 12G9, 5A3) or polyclonal antibodies (CUT specific to the last 
seven amino acids of utrophin, and previously characterized [24]). The 
use of secondary antibody coupled to phosphatase alkaline (1:5000 
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dilution, Jackson ImmunoResearch Laboratory) allowed visualization 
of the protein band with /?-nitroblue tetrazolium, and 5-bromo-4 
chloro-3 indoylphosphate substrate, as previously described [24-27]. 
The following proteins were used as molecular mass markers in all 
cases: myosin (199 kDa), ß-galactosidase (120 kDa), bovine serum 
albumin (87 kDa) and ovalbumin (48 kDa) from BIORAD. 
3. Results 
3.1. Comparative immunofluorescen.ee analyses 
On similar rabbit skeletal muscle cross-sections, we com-
pared the expression of vascular smooth muscle dystrophin 
and utrophin in two ways: (i) large versus small vessels and 
(ii) arteries versus veins. 
In large vessels, labelling was successful with all antibodies 
in arteries and veins; dystrophin and utrophin were present in 
both structures (Fig. 1). With no first antibody, only the nat-
ural fluorescence of elastine was visible in the large artery 
present in the cross-section (Fig. 1A). The 5B1 antibody 
faintly stained artery walls, but more positively revealed the 
presence of utrophin in the vein walls (Fig. IB). With a more 
intense image, 12B6 allowed detection of utrophin in veins 
and more convincingly in the artery walls (Fig. 1C). The 
monoclonal antibody 5G5 (as well as 12G9) showed similar 
positive images concerning the presence of dystrophin in both 
structures (Fig. ID). The cumulated presence of both utrophin 
and dystrophin, in accordance with the specificity of the 5A3 
antibody, was clearly revealed in both vascular structures 
(Fig. IE). 
When small veins and arteries were analysed (Fig. 2), the 
comparative images differed markedly from those presented in 
Fig. 1. Utrophin, detected with the specific monoclonal anti-
bodies 5B1 or 12B6, was found in both small vessels (Fig. 2C), 
while dystrophin detected with 5G5 was present in small ar-
teries, but absent from small veins, as presented in Fig. 2B. 
The pooled image was clearly shown (Fig. IE) when using 
5A3 antibody which detects dystrophin and utrophin (Fig. 
2D). 
3.2. Comparative Western blot analyses 
For more detailed analysis of these results, crude protein 
extractions were carried out on isolated large arteries and 
veins (it was impossible to separate small vessels from one 
another and from the muscle structure in order to obtain 
pure small artery and vein extracts). The comparative Western 
blot analyses are presented in Fig. 3. An MT 400 kDa protein 
band was detected with all antibodies in each extract, and 
only the specific utrophin antibody 5B1 cross-reacted with a 
new MT 80 kDa protein band present in artery and vein ex-
tracts. This new protein band (Fig. 4, lane 2) was also de-
tected with the CUT utrophin-specific polyclonal antibody, 
which also identified a 400 kDa protein in vessel-specific crude 
extracts, corresponding to the full-length DRP1. In rabbit 
sciatic nerve crude extracts, the CUT polyclonal antibody 
identified only a 400 kDa protein band corresponding to 
DRP1, particularly abundant in this tissue (Fig. 4, lane 1). 
This new 80 kDa protein band was not revealed with 5A3, 
which detected both utrophin and dystrophin C-terminal 
parts, or with 12G9 specific to the C-terminal part of dystro-
Fig. 1. Comparative detections of dystrophin and utrophin in large artery and vein walls. A: Muscle cross-section showing both artery and 
vein blood vessels after incubation with only the second fluorescent antibody. Seriated sections were then viewed in (B) and (C) with two differ-
ent utrophin specific antibodies (5B1 and 12B6), in (D) with a dystrophin antibody (5G5), and in (E) with a universal antibody detecting both 
dystrophin and utrophin (5A3). Bar = 20 urn. 
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Fig. 2. Comparative detections of dystrophin and utrophin in small artery and vein walls. Panel (A) corresponds to the control, panel (B) to 
dystrophin monoclonal antibody 12G9, panel (C) to utrophin monoclonal antibody 5B1, and panel (E) to utrophin and dystrophin monoclonal 
antibody 5A3. Small arteries are indicated as (a) and small veins as (v). Bar = 20 μpiι. 
phin. In addition, neither Dys 2, specific to the dystrophm C- in artery and vein walls with a panel of specific antibodies 
terminal end, nor 5F3, specific to the Dp 71 C-terminal part highlighted a clear difference between large and small vessels. 
[23], were able to reveal this new protein band. Dystrophin and utrophin were both expressed in large arteries 
and veins. Conversely, dystrophin was absent in small veins, 
4. Discussion whereas it was always present in small arteries and utrophin 
appeared in all small vessels. 
Systematic analysis of dystrophin and utrophin expression These results indicate that dystrophin is actively involved in 
Fig. 3. Western blot analysis of crude protein extracts from isolated large artery and large vein smooth muscles. Immunoblot detections with 
specific monoclonal antibodies directed against utrophin (5B1), dystrophin (12G9) and dystrophin/utrophin (5A3). Identifications were obtained 
in all crude extracts from isolated arteries (a) or veins (v) for 400 kDa proteins. With 5B1, another new 80 kDa protein band was detected in 
these extracts in both tissues. T corresponds to high molecular mass standard proteins obtained from BIORAD. 
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Fig. 4. Comparative Western blot analysis in nerve and vessel crude 
extracts. Crude extracts from isolated sciatic nerves (1) and vessels 
(2) were revealed with the CUT utrophin-specific polyclonal anti-
body directed against the last amino acid of utrophin. Only vessel 
extracts were found to contain the new 80 kDa protein band. 
mechanical resistance of the muscle membrane, which is es-
sential in large arteries, large veins and small arteries. These 
vessels have an active role in blood circulation and have con-
tractile properties, in contrast to small veins which passively 
drain blood. Dystrophin's mechanical role could involve its 
actin binding capacities, which (as recently reported [28]) can 
be increased by calmodulin-calcium binding, but also modu-
lated by specific phosphorylation of the dystrophin molecule 
[29]. This dystrophin property clearly differs from those of 
utrophin, which binds F-actin. However, this latter complex 
is dissociated by calmodulin-calcium complex formation [30], 
leading to inefficient reinforcement of the F-actin network 
during contraction. There is a clear difference in the actin 
binding properties of dystrophin and utrophin. 
In contrast, utrophin may have an important role in the 
correct assembly of muscle membrane proteins, while also 
having an architectural function in this structure. Utrophin 
was detected in all vascular structures, i.e. in the walls of all 
sizes of arteries and veins, as well as microvessels. The struc-
tural role of utrophin presented here is in full agreement with 
its synthesis as a dystrophin precursor, at least in skeletal 
muscles, but with progressive replacement by dystrophin dur-
ing development [31,32]. It is also known that even overex-
pression of utrophin [33,34] in the muscles of DMD patients 
cannot provide the membrane with efficient long-term resist-
ance when dystrophin is absent [18,28,29]. This overexpression 
may delay degeneration of the muscle membrane, but not 
compensate for an absence of dystrophin, which has also 
been reported for cardiac muscle [24]. Recently, utrophin 
was overexpressed in transgenic mdx mice [35], thus bringing 
serum creatine-kinase levels back to normal. Our results 
showed that utrophin was less efficient than dystrophin in 
terms of its participation in the active work required for blood 
circulation through arteries and large veins. Recorded meas-
urements at muscle contraction will be required to determine 
whether full recovery of muscle performance in transgenic 
mdx mice overexpressing utrophin has been obtained, as de-
scribed in muscles with mini-dystrophin expression [36]. 
The new 80 kDa protein band, only detected with the 5B1 
monoclonal antibody and CUT polyclonal antibody, may be 
a new short product belonging to the utrophin family accord-
ing to the specificity of the antibodies used. The CUT poly-
clonal antibody, which was directed against the last seven 
amino acids of utrophin, revealed that the 80 kDa protein 
contained this specific C-terminal sequence and could be con-
sidered as a short utrophin product. This is supported by the 
multitude of previously reported short utrophin products de-
tected using specific utrophin monoclonal antibodies [37]. 
However, cDNA sequencing will be required before clear 
membership to this protein family can be established. The 
roles of such related short proteins should be studied in detail. 
In conclusion, the present analysis of dystrophin and utro-
phin content in small arteries and veins sheds further light on 
the specific function of these two homologous proteins. The 
combination of immunofluorescence and Western blot analy-
ses provided complementary information. We assume, from 
the data summarized in Fig. 5, that dystrophin has a mechan-
ical role in muscle membranes, i.e. participating in the con-
tractile performance of artery and large vein walls, while utro-
phin is a structural protein essential for correct construction 
of all vessels. Structure/function relationships in each type of 
muscle membrane system (skeletal and vascular smooth 
muscles) should be clarified to determine the molecular patho-
genesis of Duchenne muscular dystrophy. The results of this 
study provide background information that will be critical for 
successful therapy. 
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